Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | VDR | P11473 | 5/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9917308 | 0.81 | CRHBP (0.47) | ESR1KDM4E | |
| SCHEMBL12232284 | 0.81 | CA2 (0.48) | KDM4EPDE4B | |
| SCHEMBL12207793 | 0.81 | ESR1 (0.37) | ESR1AAK1 | |
| SCHEMBL25986451 | 0.80 | ESR1 (0.39) | FFAR4FFAR1ESR1KDM4E | |
| SCHEMBL11959661 | 0.79 | L3MBTL1 (0.49) | KDM4EVDRCYP2C9MRGPRX4 | |
| SCHEMBL2625771 | 0.76 | SSTR4 (0.49) | KDM4ECYP2C9MRGPRX4 | |
| SCHEMBL10645049 | 0.76 | KDM4E (0.39) | ESR1KDM4EVDRAAK1HDAC3 | |
| SCHEMBL26397831 | 0.74 | PTGS1 (0.46) | ESR1KDM4E | |
| SCHEMBL11951589 | 0.74 | ACHE (0.43) | KDM4EVDRAAK1 | |
| SCHEMBL12207798 | 0.73 | ALDH1A1 (0.48) | KDM4ECYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170232017-A1 | TREATMENT OF CANCER | THRESHOLD PHARMACEUTICALS, INC. (US) | 2017-08-17 | — | — | US | disclosed |
| US-20160158253-A1 | TREATMENT OF PANCREATIC CANCER WITH A COMBINATION OF A HYPOXIA-ACTIVATED PRODRUG AND A TAXANE | MERCK PATENT GMBH (DE) | 2016-06-09 | — | — | US | disclosed |
| US-20160045522-A1 | Treatment of Cancer | THRESHOLD PHARMACEUTICALS, INC. (US) | 2016-02-18 | — | — | US | disclosed |
| US-9254299-B2 | Administration of hypoxia activated prodrugs in combination with Chk1 inhibitors for treating cancer | THRESHOLD PHARMACEUTICALS, INC. (US) | 2016-02-09 | — | — | US | disclosed |
| US-9226932-B2 | Phosphoramidate alkylator prodrugs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2016-01-05 | — | — | US | disclosed |
| US-20150005263-A1 | ADMINISTRATION OF HYPOXIA ACTIVATED PRODRUGS IN COMBINATION WITH CHK1 INHIBITORS FOR TREATING CANCER | THRESHOLD PHARMACEUTICALS, INC. | 2015-01-01 | — | — | US | disclosed |
| US-20150005262-A1 | HYPOXIA ACTIVATED PRODRUGS AND MTOR INHIBITORS FOR TREATING CANCER | THRESHOLD PHARMACEUTICALS, INC. | 2015-01-01 | — | — | US | disclosed |
| US-20140171389-A1 | METHODS FOR TREATING CANCER | THRESHOLD PHARMACEUTICALS, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140170240-A1 | Phosphoramidate Alkylator Prodrugs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140072624-A1 | UNIT DOSE FORM FOR ORAL ADMINISTRATION | THRESHOLD PHARMACEUTICALS, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-8664204-B2 | Phosphoramidate alkylator prodrugs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-20130303778-A1 | PHOSPHORAMIDATE ALKYLATOR PRODRUGS | THRESHOLD PHARMACEUTICALS, INC. | 2013-11-14 | — | — | US | disclosed |
| US-20130296273-A1 | TREATMENT OF BLOOD CANCER | THRESHOLD PHARMACEUTICALS, INC. | 2013-11-07 | — | — | US | disclosed |
| US-8507464-B2 | Phosphoramidate alkylator prodrugs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-20110251159-A1 | Phosphoramidate Alkylator Prodrugs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-8003625-B2 | Phosphoramidate alkylator prodrugs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20100137254-A1 | PHOSPHORAMIDATE ALKYLATOR PRODRUGS | IMMUNOGENESIS, INC. | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005263-A1 | ADMINISTRATION OF HYPOXIA ACTIVATED PRODRUGS IN COMBINATION WITH CHK1 INHIBITORS FOR TREATING CANCER | CHEK1, CHEK2, HIF1AN | FFAR4 4230/4885FFAR1 3703/4885ESR1 2830/4885 |
| US-20100137254-A1 | PHOSPHORAMIDATE ALKYLATOR PRODRUGS | TYMP, PAICS, PNP | FFAR4 987/4885FFAR1 1325/4885ESR1 1579/4885 |
| US-20160045522-A1 | Treatment of Cancer | HIF1AN, HIF1A, EGLN3 | FFAR4 1224/4885FFAR1 1816/4885ESR1 3160/4885 |
| US-20160158253-A1 | TREATMENT OF PANCREATIC CANCER WITH A COMBINATION OF A HYPOXIA-ACTIVATED PRODRUG AND A TAXANE | HIF1AN, HIF1A, RNASE1 | FFAR4 896/4885FFAR1 847/4885ESR1 3930/4885 |
| US-20110251159-A1 | Phosphoramidate Alkylator Prodrugs | TYMP, PAICS, PNP | FFAR4 982/4885FFAR1 1327/4885ESR1 1611/4885 |
| US-20150005262-A1 | HYPOXIA ACTIVATED PRODRUGS AND MTOR INHIBITORS FOR TREATING CANCER | HIF1AN, HIF1A, MTOR | FFAR4 980/4885FFAR1 1062/4885ESR1 1058/4885 |
| US-20140171389-A1 | METHODS FOR TREATING CANCER | HIF1AN, HYOU1, HIF1A | FFAR4 4045/4885FFAR1 3198/4885ESR1 2656/4885 |
| US-20140072624-A1 | UNIT DOSE FORM FOR ORAL ADMINISTRATION | HIF1AN, HIF1A, HYOU1 | FFAR4 985/4885FFAR1 1005/4885ESR1 2943/4885 |
| US-20170232017-A1 | TREATMENT OF CANCER | HIF1AN, HIF1A, EGLN3 | FFAR4 1224/4885FFAR1 1816/4885ESR1 3160/4885 |
| US-20130296273-A1 | TREATMENT OF BLOOD CANCER | HIF1AN, HIF1A, MCL1 | FFAR4 1709/4885FFAR1 2192/4885ESR1 1995/4885 |
| US-20140170240-A1 | Phosphoramidate Alkylator Prodrugs | TYMP, PAICS, PNP | FFAR4 982/4885FFAR1 1327/4885ESR1 1611/4885 |
| US-20130303778-A1 | PHOSPHORAMIDATE ALKYLATOR PRODRUGS | TYMP, PAICS, PNP | FFAR4 982/4885FFAR1 1327/4885ESR1 1611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.